Close Menu

NEW YORK – Enzo Biochem reported after the close of the market on Thursday that revenues for its fiscal second quarter ticked up less than 1 percent year over year, as the Protecting Access to Medicare Act (PAMA) continued to negatively affect reimbursements from Medicare and third-party payers.

For the three months ended Jan. 31, the diagnostics company reported total revenues of $19.4 million, compared to $19.3 million in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.